Overview

Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)

Status:
Unknown status

Trial end date:
2019-07-01

Target enrollment:

Participant gender:

Summary

This is a Phase 4, randomized clinical trial to evaluate whether addition of Vorapaxar 2.08 mg daily vs. placebo daily on background antiplatelet therapy, prescribed for 6 months to patients with established peripheral artery disease (PAD) and Intermittent Claudication (IC) treated with standard medical therapy (SMT) would lead to an improvement in the peak walking time (PWT).

Phase:

Phase 4

Details

Lead Sponsor:

North Texas Veterans Healthcare System

Treatments:

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Aspirin
Enzyme Inhibitors
Thrombin
Vorapaxar